Section 6 of 6
References
135 sources
- Abraham et al. (2020) (opens in a new tab)
- Abraham et al. (2025) (opens in a new tab)
- Aguiar-Ibáñez et al. (2025) (opens in a new tab)
- American Cancer Society (2026) (opens in a new tab)
- Ang et al. (2010) (opens in a new tab)
- Argiris et al. (2014) (opens in a new tab)
- Bedi et al. (2012) (opens in a new tab)
- Biau et al. (2026) (opens in a new tab)
- Bicara Therapeutics breakthrough therapy designation announcement (2025) (opens in a new tab)
- Bicara Therapeutics clinical trial protocol BCA101X1101 (2024) (opens in a new tab)
- Bicara Therapeutics expanded access policy (opens in a new tab)
- Bicara Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
- Bicara Therapeutics Form 10-K (2026) (opens in a new tab)
- Bicara Therapeutics Form 10-Q (2026) (opens in a new tab)
- Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025) (opens in a new tab)
- Bicara Therapeutics fourth quarter and full year 2025 results announcement (2026) (opens in a new tab)
- Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026) (opens in a new tab)
- Bicara Therapeutics presentation (2026) (opens in a new tab)
- Bicara Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
- Bicara Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
- Bicara Therapeutics three-year overall survival announcement (2026) (opens in a new tab)
- Black et al. (2023) (opens in a new tab)
- Black et al. (2024) (opens in a new tab)
- Boreddy et al. (2023) (opens in a new tab)
- Borse et al. (2022) (opens in a new tab)
- Bradbury et al. (2025) (opens in a new tab)
- Britton et al. (2024) (opens in a new tab)
- Bulbul et al. (2022) (opens in a new tab)
- Burtness et al. (2019) (opens in a new tab)
- Burtness et al. (2022) (opens in a new tab)
- Cabezas-Camarero et al. (2025) (opens in a new tab)
- Cancer Genome Atlas Network (2015) (opens in a new tab)
- Chaturvedi et al. (2011) (opens in a new tab)
- Chung et al. (2025) (opens in a new tab)
- ClinicalTrials.gov NCT04429542 (opens in a new tab)
- ClinicalTrials.gov NCT04534205 (opens in a new tab)
- ClinicalTrials.gov NCT06064877 (opens in a new tab)
- ClinicalTrials.gov NCT06525220 (opens in a new tab)
- ClinicalTrials.gov NCT06788990 (opens in a new tab)
- ClinicalTrials.gov NCT06790966 (opens in a new tab)
- ClinicalTrials.gov NCT07276399 (opens in a new tab)
- ClinicalTrials.gov NCT07465276 (opens in a new tab)
- ClinicalTrials.gov NCT07529873 (opens in a new tab)
- ClinicalTrials.gov NCT07552558 (opens in a new tab)
- ClinicalTrials.gov NCT07807163 (opens in a new tab)
- Cohen et al. (2019) (opens in a new tab)
- Costantino et al. (2025) (opens in a new tab)
- Dzienis et al. (2024) (opens in a new tab)
- EU CTIS 2024-519654-37-00 (opens in a new tab)
- EU CTIS 2026-526741-10-00 (opens in a new tab)
- Fakhry et al. (2014) (opens in a new tab)
- Faquin et al. (2025) (opens in a new tab)
- FDA (2018) (opens in a new tab)
- FDA (2023) (opens in a new tab)
- FDA (2024) (opens in a new tab)
- FDA (2026) (opens in a new tab)
- FDA List of Cleared or Approved Companion Diagnostic Devices (2026) (opens in a new tab)
- FDA press announcement (2026) (opens in a new tab)
- Ferrarotto et al. (2025a) (opens in a new tab)
- Ferrarotto et al. (2025b) (opens in a new tab)
- Ferrarotto et al. (2026a) (opens in a new tab)
- Ferrarotto et al. (2026b) (opens in a new tab)
- Ferris et al. (2016) (opens in a new tab)
- Fisher et al. (2018) (opens in a new tab)
- Forastiere et al. (1992) (opens in a new tab)
- Fraslin et al. (2025) (opens in a new tab)
- Genmab LiGeR-HN1 interim analysis announcement (2026) (opens in a new tab)
- Genmab petosemtamab phase 2 update announcement (2026) (opens in a new tab)
- Gibson et al. (2005) (opens in a new tab)
- Guigay et al. (2021) (opens in a new tab)
- Haddad et al. (2020) (opens in a new tab)
- Hanna et al. (2025) (opens in a new tab)
- Hanna et al. (2026) (opens in a new tab)
- Harrington et al. (2023) (opens in a new tab)
- Hernando-Calvo et al. (2025) (opens in a new tab)
- Hihara et al. (2026) (opens in a new tab)
- ImClone ERBITUX prescribing information (2021) (opens in a new tab)
- Janot et al. (2008) (opens in a new tab)
- Janssen RYBREVANT FASPRO prescribing information (2026) (opens in a new tab)
- Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026) (opens in a new tab)
- Johnson & Johnson OrigAMI-4 cohort 5 announcement (2026) (opens in a new tab)
- Johnson et al. (2020) (opens in a new tab)
- Kaczmar et al. (2025) (opens in a new tab)
- Kaczmar et al. (2026a) (opens in a new tab)
- Kaczmar et al. (2026b) (opens in a new tab)
- Kao et al. (2026) (opens in a new tab)
- Keam et al. (2021) (opens in a new tab)
- Kim et al. (2012) (opens in a new tab)
- Lee et al. (2020) (opens in a new tab)
- Lee et al. (2025) (opens in a new tab)
- Lewis et al. (2025) (opens in a new tab)
- Li et al. (2025) (opens in a new tab)
- Lilly ERBITUX cost information (2026) (opens in a new tab)
- Llop et al. (2024) (opens in a new tab)
- Machiels et al. (2025) (opens in a new tab)
- Machtay et al. (2008) (opens in a new tab)
- Mady et al. (2025) (opens in a new tab)
- Mandal et al. (2016) (opens in a new tab)
- Massa et al. (2019) (opens in a new tab)
- Massa et al. (2022) (opens in a new tab)
- Mauskopf et al. (2007) (opens in a new tab)
- Merck KEYTRUDA cost information (2026) (opens in a new tab)
- Merck KEYTRUDA prescribing information (2026) (opens in a new tab)
- Meregaglia and Cairns (2017) (opens in a new tab)
- Mody et al. (2021) (opens in a new tab)
- National Cancer Institute (2021) (opens in a new tab)
- National Cancer Institute Laryngeal Cancer Treatment PDQ (2025) (opens in a new tab)
- National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025) (opens in a new tab)
- National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025) (opens in a new tab)
- Nguyen et al. (2023) (opens in a new tab)
- Pfister et al. (2020) (opens in a new tab)
- Reverdy et al. (2023) (opens in a new tab)
- Rischin et al. (2022) (opens in a new tab)
- SEER Cancer Stat Facts Laryngeal Cancer (2026) (opens in a new tab)
- SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026) (opens in a new tab)
- Senkomago et al. (2019) (opens in a new tab)
- She et al. (2022) (opens in a new tab)
- Siegel et al. (2026) (opens in a new tab)
- Sullivan et al. (2014) (opens in a new tab)
- Sung et al. (2026) (opens in a new tab)
- Swiecicki et al. (2026) (opens in a new tab)
- Tahara et al. (2025) (opens in a new tab)
- Tortochaux et al. (2011) (opens in a new tab)
- Vermorken et al. (2008) (opens in a new tab)
- Wakasaki et al. (2020) (opens in a new tab)
- WHO Drug Information Proposed INN List 130 (2023) (opens in a new tab)
- WHO Drug Information Recommended INN List 92 (2024) (opens in a new tab)
- Wissinger et al. (2014) (opens in a new tab)
- Wong et al. (2026a) (opens in a new tab)
- Wong et al. (2026b) (opens in a new tab)
- Xie et al. (2026) (opens in a new tab)
- Ye et al. (2024) (opens in a new tab)
- Yilmaz et al. (2023) (opens in a new tab)
- Zandberg et al. (2026) (opens in a new tab)
- Zheng et al. (2026) (opens in a new tab)